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Gene Therapy of Bone Morphogenetic
Protein for Periodontal Tissue Engineering
Q-M. Jin,* O. Anusaksathien,* S.A. Webb,* R.B. Rutherford,* and W.V. Giannobile*
Background: The reconstruction of lost periodontal support
including bone, ligament, and cementum is a major goal of ther-
apy. Bone morphogenetic proteins (BMPs) have shown much
potential in the regeneration of the periodontium. Limitations of
BMP administration to periodontal lesions include need for high-
dose bolus delivery, BMP transient biological activity, and low
bioavailability of factors at the wound site. Gene transfer offers
promise as an alternative treatment strategy to deliver BMPs to
periodontal tissues.
Methods: This study utilized ex vivo BMP-7 gene transfer to
stimulate tissue engineering of alveolar bone wounds. Syngeneic
dermal fibroblasts (SDFs) were transduced ex vivo with aden-
oviruses encoding either green fluorescent protein (Ad-GFP or
control virus), BMP-7 (Ad-BMP-7), or an antagonist of BMP
bioactivity, noggin (Ad-noggin). Transduced cells were seeded
onto gelatin carriers and then transplanted to large mandibular
alveolar bone defects in a rat wound repair model.
Results: Ad-noggin treatment tended to inhibit osteogenesis
as compared to the control-treated and Ad-BMP-7-treated spec-
imens. The osseous lesions treated by Ad-BMP-7 gene delivery
demonstrated rapid chrondrogenesis, with subsequent osteo-
genesis, cementogenesis and predictable bridging of the peri-
odontal bone defects.
Conclusion: These results demonstrate the first successful
evidence of periodontal tissue engineering using ex vivo gene
transfer of BMPs and offers a new approach for repairing peri-
odontal defects. J Periodontol 2003;74:202-213.
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Periodontal diseases are characterizedby an inflammatory reaction of gingi-val tissues in response to bacterial
biofilms that accumulate on tooth root sur-
faces resulting in loss of alveolar bone,
cementum, and periodontal ligament
(PDL). The field of tissue engineering offers
great promise for periodontal repair to
restore, maintain, or enhance tissues and
organs.1,2 Various reconstructive proce-
dures have been pursued to re-engineer
lost tooth support such as bone autografts,
allografts, or cell occlusive barrier mem-
branes. In general, these therapies are lim-
ited in both predictability and extent of
healing response.3
Bone morphogenetic proteins (BMPs)
are multifunctional growth factors belong-
ing to the transforming growth factor β
(TGF-β) superfamily (see reference 4 for
review). BMPs are powerful regulators of
cartilage and bone formation during
embryonic development and regeneration
in post-natal life. Some BMPs also partic-
ipate in the development and repair of
extraskeletal tissues and organs such as
the brain, kidney, and nerves.5 A striking
and discriminatory feature of some of these
proteins is their ability to induce de novo
endochondral osteogenesis in ectopic sites
(e.g., skin or muscle).6 BMP activities are
not only modulated through gene expres-
sion and protein processing, but by the
interaction with antagonists such as nog-
gin.7 Noggin expression is essential for
proper skeletal development and unregu-
lated BMP activity in the noggin null mutant
results in excess cartilage and failure of the
initiation of joint formation.8 Furthermore,
application of noggin to embryonic tooth
bud explants can switch tooth type from
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incisors to molars, hence demonstrating a potential
critical role of noggin in tooth development.9
Several studies have demonstrated the expression of
BMPs in tooth development and periodontal repair.10-12
BMP-7 potently stimulates alveolar bone regeneration
around teeth,13 endosseous oral implants,14 and in
maxillary sinus floor augmentation procedures.15 How-
ever, to date human trials have failed to equal results
reported in preclinical studies.16 The reasons for this
are unclear; however, a major limitation with growth
factor delivery to periodontal wound sites is the
extremely short biological activity of the factors in vivo.
This phenomenon is presumably due to proteolytic
degradation, rapid diffusion, and the solubility of the
delivery vehicle in the hostile wound healing environ-
ment.17 Therefore, DNA delivery systems may be an
alternative strategy for growth factor application in tis-
sue engineering.16,18,19 Ex vivo gene transfer has
demonstrated success in a variety of orthopedic indi-
cations including non-union fractures and craniofacial
defects.20-22 In the present study we show that tar-
geted, local gene delivery of BMP-7 can repair lost
periodontal supporting structures.
MATERIALS AND METHODS
In Vitro Adenoviral Gene Transfer of BMP-7 and
Noggin
For gene transfer studies, recombinant adenoviruses
AdCMVGFP (adenovirus encoding green fluorescent
protein [GFP] driven by the cytomegalovirus promoter
[CMV]) and AdCMVBMP-7 (adenovirus encoding murine
BMP-7 or osteogenic protein-1 [OP-1]) were constructed
as previously described.23,24 The AdCMVnoggin (ade-
novirus encoding human noggin devoid of the heparin
binding site) construct was generously donated (gift of
A.N. Economides, Regeneron Pharmaceuticals, Inc. Tar-
rytown, New York).25 Titers of the virus stocks were
determined on embryonic kidney 293 cells by plaque
assay and expressed as the number of plaque forming
units (pfu) per ml as previously described.26,27
Cell Culture and Gene Transfer
Primary cultures of rat syngeneic dermal fibroblasts
(SDFs) were utilized as previously described for ex vivo
gene transfer.21 Low passage cells (P4-P6) were plated
at a density of 50,000 cells/cm2 in Dulbecco’s modi-
fied Eagle medium (DMEM)† supplemented with 10%
fetal bovine serum‡ (FBS), antibiotics (100 units/ml
penicillin and 100 µg/ml streptomycin†), and 2 mM
glutamine. After incubation overnight (O/N) in a
humidified atmosphere of 5% CO2 in air at 37°C, the
cells were transduced with 1 of 3 different recombinant
adenoviruses (Ad-GFP, Ad-BMP-7 or Ad-noggin) at a
multiplicity of infection (MOI) range of 2 to 200 in
serum-free DMEM for 5 hours while shaking. Next, the
same volume of DMEM supplemented with 4% FBS
was added and the cells were incubated O/N. After
24 hours, the medium was changed to DMEM con-
taining 10% FBS for an additional 24 hours. For the final
24 hours the cells were transferred to serum-free DMEM
and then the medium was collected for analysis by
Western blotting.
Alkaline Phosphatase Activity and Cell
Proliferation
The SDFs were infected with recombinant adenoviruses
Ad-GFP, Ad-BMP-7, or Ad-noggin at MOI = 200 for
24 hours under the same conditions described above.
Then the medium was changed to DMEM containing
10% FBS during the experimental period. The begin-
ning of adenovirus transduction was designated as day
0. After 10 days of culture, the cells were collected
and then lysed using a solution containing 0.2% NP-
40, 10 mM Tris-HCl, 1 mM MgCl2, pH 7.4. DNA con-
tent as a measure of cell growth was measured using
a fluorochrome§ via a fluorometer. The alkaline phos-
phatase (AP) activities of the cells at each designated
time point were measured with an AP kit§ according
to the manufacturer’s instructions.
Northern Blotting
The total cellular RNA of the SDFs transduced by the
adenoviruses was extracted using a modified guani-
dine thiocyanate procedure with Trizol reagent.28 Ten
micrograms of total RNA was denatured, fractionated
on 6% formaldehyde/1.2% agarose gels, transferred
onto nylon membranes,¶ and immobilized.# The blots
were then hybridized with 32P-labeled probes (BMP-
7/OP-1 cDNA (kind gift of H. Opermann, Stryker
Biotech, Hopkinton, Massachusetts; noggin cDNA was
a kind gift of A.N. Economides, Regeneron) generated
from randomly primed cDNA** and exposed to film
with intensifying screens at −70°C for 6 to 24 hours.
To evaluate the relative loading of RNA samples, 18S
was used as a standard.
Western Blotting
The serum-free media (above) were dialyzed against
distilled water containing proteinase inhibitors and
lyophilized. The lyophilized samples were dissolved in
60 µl SDS-PAGE loading buffer (2% SDS, 4M urea, 5%
β-mercaptoethanol, 7% glycerol, 10 mM Tris-HCl,
0.002% bromophenol blue pH 6.8). Fifty microliters of
each sample was fractionated by SDS-PAGE on 15%
gels for BMP-7 detection, while 1 µl of each sample
was fractionated by the same gel for noggin detection.
The fractionated proteins in the gels were then elec-
† Gibco BRL Life Technologies, Inc., Grand Island, NY.
‡ Gemini Bio-Products, Woodland, CA.
§ Sigma Diagnostics, Inc., St. Louis, MO.
  Hoefer Scientific, San Francisco, CA.
¶ Duralon UV, Stratagene, Inc., La Jolla, CA.
#  Stratalink, Stratagene, Inc.
** Rediprime, Amersham, Arlington Heights, IL.
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antibody (kind gift of D. Rueger,
Stryker Biotech, Hopkinton,
Massachusetts) was used at a
dilution of 1:4,000 and secondary
antibody of horseradish peroxi-
dase-conjugated goat anti-rabbit
immunoglobulin G was used at a
dilution of 1:35,000. Rat anti-
human noggin antibody (RP57-
16; gift of Regeneron) was used
at a concentration of 20 ng/ml
and secondary antibody of horse-
radish peroxidase-conjugated goat
anti-rat immunoglobulin G was
used at a dilution of 1:12,000.
Immunoreactivity was determined
using an ECL kit.‡‡
All animal procedures were
performed under the University
of Michigan Unit for Laboratory
Animal Medicine Guidelines.
Ex Vivo Gene Transfer to
Periodontal Alveolar Bone Wounds
We utilized a modified periodontal alveolar bone defect
model as described by King et al.29 In brief, 25 Lewis
rats§§ (approximate weight 250 to 300 g) had osseous
defects created under general anesthesia using keta-
mine and xylazine.¶¶ The osteotomies were created
by initially preparing an extraoral 2 cm superficial skin
incision at the lower border of the mandible bilaterally.
The superficial fascia and underlying masseter mus-
cle were separated with sharp dissection and the lig-
amentary attachment of the masseter muscle to bone
was severed at its inferior base, and both the masseter
and periosteum were elevated from the bone to expose
the buccal plate of the mandible. The oral mucosa on
the superior wall of the surgically created osteotomy
was identified, and its attachment to the intraoral ker-
atinized gingival margin was maintained during defect
preparation. The bone overlying the mandibular first
molar was removed with a high speed handpiece under
saline irrigation while visualizing with a surgical micro-
scope. The buccal and distal roots of the first molar
tooth and the buccal root of the second molar tooth
were carefully denuded of periodontal ligament, over-
lying cementum, and superficial dentin. The defects
measured approximately 0.3 × 0.2 cm in dimension.
One million SDFs were plated in 100 cm2 culture
dishes in DMEM containing 10% FBS, supplemented
with 100 units/ml penicillin/streptomycin, and 2 mM
glutamine. One million cells were then transduced with
200 MOI of Ad-GFP, Ad-BMP-7 or Ad-noggin as
described above for 24 hours. At the time of surgery,
106 transduced SDFs were seeded into gelatin
sponges## measuring approximately 3 × 2 × 2 mm
and then transplanted ex vivo to the periodontal
wounds. Treatment was randomly assigned to Ad-GFP
control-treated, Ad-noggin-treated, or Ad-BMP-7 SDFs
on one side of the arch while another treatment was
randomly assigned to the contralateral side (n = 4 to
7 animals/group). The transduced SDFs seeded in the
gelatin sponges were gently placed into the mandibu-
lar osteotomy defects. The internal wounds were
approximated with resorbable 5-0 chromic gut sutures
and the external skin incisions closed with surgical
staples. The animals were administered supplemental
antibiotics (ampicillin 268 µg/ml of drinking water)
given daily for up to 14 days. The study design is sum-
marized in Figure 1.
Descriptive Histology
Rats were sacrificed at 3, 10, 21, and 35 days after
surgery and block biopsies placed into Bouin’s fixa-
tive,*** decalcified with 10% vol/vol acetic acid, 4%
vol/vol formaldehyde, 0.85% NaCl for 2 to 3 weeks,
and then embedded in paraffin. The specimens were
cut into 4 to 5 µm coronal sections and stained with
†† Immuno-Blot, Bio-Rad Laboratories, Hercules, CA.
‡‡  Amersham Pharmacia Biotech, Inc. Piscataway, NJ.
§§ Charles River, Wilmington, MA.
 Ketaset, Fort Dodge Animal Health, Fort Dodge, IA.
¶¶ AnaSet Lloyd Laboratories, Shenandoah, IA.
## Gelfoam, Upjohn, Kalamazoo, MI.
*** Polysciences, Warrington, PA.
Figure 1.
Ex vivo gene transfer to periodontal alveolar bone wounds. Syngeneic dermal fibroblasts (SDFs) were
expanded in culture following biopsy, then transduced with recombinant adenoviruses (Ad-GFP,Ad-
BMP7, or Ad-noggin).After 24 hours, cells were seeded into gelatin sponges and placed into large
mandibular osseous defects created in 25 Lewis rats. Block biopsies were harvested and analyzed
using conventional histology, immunohistochemistry, and histomorphometry.
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hematoxylin and eosin (H & E) or toluidine blue for
visualization by light or polarized light microscopy.
Immunohistochemistry
Immunodetection of noggin and BMP-7 in the peri-
odontal lesions following gene transfer were performed
using immunohistochemistry. The sections were
deparaffinized with xylene, rehydrated with gradient
alcohol, and rinsed with phosphate buffer saline (PBS).
Antigen retrieval was performed by soaking the sec-
tions with 10 mM sodium citrate, pH 6 at 90° to 95°C
for 15 minutes, washed twice with PBS, followed by
0.1% trypsin digestion in PBS at 37°C for 10 minutes.
The sections were washed twice with PBS. Endoge-
nous peroxidase was blocked with 0.3% H2O2 in PBS
for 30 minutes at room temperature (RT) and washed
twice again with PBS. Nonspecific binding was blocked
using 2% goat normal serum for 30 minutes at RT.
The sections were incubated with polyclonal rabbit
anti-human BMP-7 (1:2,000) for 1 hour at RT and then
washed 3 times with PBS. Goat anti-rabbit secondary
antibody (1:500) was incubated for 30 minutes at RT
using a commercial kit††† according to the manufac-
turer’s protocol. For noggin staining, the sections were
treated in the same manner except the antigen retrieval
step was omitted. Rat biotinylated anti-human noggin
(50 µg/ml, RP57-21, [gift of Regeneron]) was incu-
bated for 1 hour at RT and washed 3 times with PBS.
Streptavidin/peroxidase complex‡‡‡ was incubated for
8 minutes. The sections were then washed 3 times
with PBS. DAB staining was performed using a DAB
substrate kit.‡‡‡ The sections were counterstained with
Gill’s hematoxylin # 1§§§ for 90 seconds, rinsed in run-
ning water for 5 minutes, dehydrated through a series
of alcohols and xylene, and then mounted with mount-
ing medium.§§§
Histomorphometry
Computer-assisted image analysis was utilized to deter-
mine the ability of gene transfer to affect periodontal
tissue repair. Specimens were captured using a micro-
scope fitted with a camera¶¶¶ for analysis using soft-
ware.### Images of coded specimens were captured
at 2, 4, 10, and 20 × magnification for histomorpho-
metric analysis. A single masked, calibrated examiner
(OA) examined all of the slides and demonstrated a
pre- and post-study calibration inter- and intra-exam-
iner error of <5% compared to a standard (WG). Sev-
eral parameters of periodontal regeneration were mea-
sured and included: 1) length of new cementum on
the distal root of the first molar was measured as the
total length of mineral-like tissue on the denuded root
surface in mm; 2) length of new bridging bone mea-
sured from the borders of the original osseous defect
(mesially-distally) in mm; and 3) density of new bone
associated with the osseous defect and gelatin carrier
in mm2. Mean values were generated for each of the
groups evaluated. The coded specimens were then
analyzed using an analysis of variance and a Fisher’s
probability of least significant difference (PLSD) mul-
tiple comparison procedure to measure statistical dif-
ferences among groups.
RESULTS
Expression of BMP-7 and Noggin Following 
Ad-BMP-7 and Ad-Noggin Gene Transfer
To examine whether Ad-BMP-7 and Ad-noggin trans-
duced cells produce and secrete immunoreactive BMP-
7 and noggin protein, cell layers and conditioned media
from transduced SDFs were collected and probed for
BMP-7 and noggin by Northern and Western blot analy-
ses, respectively. To choose the appropriate media col-
lection time for maximal protein release, a time course
by flow activated cell sorting (FACS) was performed
using the control virus Ad-GFP. FACS revealed initial
GFP fluorescence as early as 6 to 8 hours after Ad-
GFP exposure, with >95% of the cells exhibiting GFP
protein by 20 to 24 hours after transduction using a
multiplicity of infection (MOI) = 200 (data not shown).
Two days following gene transfer, cell lysates were
assessed for the expression of BMP-7 and noggin genes
by Northern analysis. A dose response of increasing
level of expression relating to MOI (2 to 200) was noted
(data not shown). The conditioned medium harvested
after 3 days was evaluated for noggin and BMP-7 pro-
tein production. Figure 2A demonstrates a Western
blot of protein that was concentrated and lyophilized
from media that was probed with monospecific BMP-7
antibody or anti-noggin antibody. Ad-BMP-7 and Ad-
noggin transduced cells produced immunoreactive pro-
tein that exhibited the same electrophoretic mobility
as purified rhBMP-7 and rhnoggin, respectively on
β-mercaptoethanol reduced samples with maximal pro-
tein expression at MOI = 200. Interestingly, transduction
of SDFs with Ad-BMP-7 also initiated the release of
immunodetectable noggin protein in these cultures (Fig.
2A, middle panel) at both MOI = 20 and 200. Figure 2B
illustrates the ability of Ad-BMP-7 to induce the expres-
sion of the osteoblastic differentiation marker alkaline
phosphatase. Cell cultures were maintained for 10 days
and demonstrated a nearly 4-fold increase in AP activ-
ity suggesting that BMP gene transfer promotes con-
version of these fibroblasts to an osteoblastic pheno-
type. By 10 days it was noted that some of the cells
were still producing protein via gene transfer; how-
ever, the percentage of cells at this time was less than
10% as shown by fluorescence of Ad-GFP-treated cells
(Fig. 2C). Evaluation of DNA content as a measure
††† Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA.
‡‡‡ Vector Laboratories.
§§§ Permount, Fisher Scientific, Fair Lawn, NJ.
 Nikon Eclipse E800, Nikon, Inc., Melville, NY.
¶¶¶ SPOT-2, Diagnostic Instruments, Inc., Sterling Heights, MI.
### Image Pro Plus, Media Cybernetics, Silver Spring, MD.
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and Noggin in Periodontal
Defects Following Gene
Transfer Via Adenoviruses
To determine the transduction of
the transplanted SDFs in vivo in
the periodontal wounds, immuno-
histochemical detection of BMP-
7 and noggin was performed at 3,
10, and 35 days after surgery. It
was noted that expression of
BMP-7 and noggin was found at
3 days following gene delivery,
however, was essentially unde-
tectable by 10 and 35 days after
surgery (data not shown). Figure 3
shows high level expression of
BMP-7 and noggin in Ad-BMP-7
and Ad-noggin treated speci-
mens, respectively. In addition,
as noted in Western blotting
experiments, Ad-BMP-7 gene
transfer elicited noggin protein
production that was detectable
immunohistochemically in some
specimens. Ad-GFP or Ad-noggin
treatment did not affect BMP-7
protein production in vivo.
BMP-7 Gene Delivery Promotes
Periodontal Tissue
Engineering In Vivo
To determine the role in vivo of
BMP and noggin gene delivery
on periodontal engineering,
SDFs transduced by Ad-GFP,
Ad-noggin, or Ad-BMP-7 were
utilized in large mandibular
alveolar bone defects. The
lesions were compared at 10
and 35 days following gene
transfer. Figure 4 illustrates a
coronal view of defects treated
by ex vivo gene transfer. Mini-
mal to no evidence of osteoge-
nesis was seen in Ad-GFP and
Ad-noggin groups at this early
timepoint. There was a prepon-
derance of macrophage-like
cells coating the gelatin im-
plants containing cells trans-
duced with Ad-noggin (Fig. 4,
Figure 2.
In vitro production of BMP-7 and noggin by adenoviruses encoding BMP-7 and noggin. Following
24 hours of serum starvation, SDFs were transduced with Ad-BMP-7,Ad-noggin or Ad-GFP at a MOI
ranging from 2 to 200. Conditioned media were collected after 48 hours, dialyzed, concentrated, and
lyophilized.The lyophilized samples were resuspended in reducing sample buffer and analyzed by
Western blotting with anti-BMP-7 or anti-noggin polyclonal antibodies. Five nanograms of either
BMP-7 or noggin were loaded as controls. Note that Ad-BMP-7 treatment resulted in
immunodetectable BMP-7 and noggin (A, top and middle panels). Ad-noggin gene transfer resulted in
noggin protein release into the medium at MOI = 20 and 200 (A, bottom panel). B illustrates SDFs
transduced with Ad-GFP,Ad-BMP-7, or Ad-noggin at MOI = 200 for 24 hours.After 10 days, the cells
were lysed and alkaline phosphatase (AP) activities of the cells were measured with an AP kit. Note
the significant increase in AP activity in Ad-BMP-7 SDFs, while no treatment (NT),Ad-GFP and Ad-
noggin-treated cells revealed no increase in AP activity. (n = 3 plates/experiment; *P <0.01). C shows
the same cells evaluated in B under fluorescence microscopy for the production of GFP. It was seen
that at this timepoint that approximately 5 to 10% of the cells demonstrated positive GFP
fluorescence (10× original magnification; UV fluorescence).
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middle panel). Interestingly, in the Ad-BMP-7 group,
cells were visualized more closely associated with
the root surface (Fig. 4f). Furthermore, defects
treated with Ad-BMP-7 demonstrated cartilage (Fig.
4e, asterisk) and limited areas of bone (Fig. 4e, open
arrows) in the majority of the defects examined. The
cartilage was found to be localized lateral to the
gelatin carrier in all of the specimens exhibiting chon-
droblast-like cells. We also found that much of the
cartilage persisted to day 21 (Fig. 5) but was com-
pletely gone by day 35. To our knowledge, this is
the first evidence of endochondral ossification in the
alveolar process following BMP exposure.
At 35 days following ex vivo gene transfer exten-
sive bone formation, bone bridging, and cementoge-
nesis with fiber insertion could be seen (via polarized
light microscopy) in most of the defects treated by
Ad-BMP-7 (n = 6; Figs. 6 and 7), while minimal osteo-
genesis and cementogenesis and lack of fiber inser-
tion was noted in the Ad-GFP (n = 7; Fig. 6a and b)
and Ad-noggin-treated (n = 4; Fig. 6c and d) animals.
Moreover, in none of the GFP or noggin-treated spec-
imens was complete bridging of the defects noted,
while 4 of the 6 animals treated with BMP-7 gene
delivery demonstrated complete bridging of the
osseous defects. Histomorphometric analysis showed
no significant differences among the groups in terms
of initial defect sizes (mean range ± SD of groups:
2.86 ± 0.37 to 2.95 ± 0.27 mm; P >0.05). Masked
histomorphometry at 35 days revealed significant
Figure 3.
Immunolocalization of BMP-7 and noggin 3 days following gene delivery of Ad-BMP-7 and Ad-noggin to periodontal alveolar bone wounds.Three days
following ex vivo gene transfer, block biopsies were harvested, fixed, decalcified and immunoprobed for the expression of BMP-7 and noggin
immunoreactivity. Note increased BMP-7 immunoreactivity within the gelatin carrier in specimens treated with Ad-BMP-7. In addition, specimens treated
with Ad-noggin expressed immunoreactivity for noggin protein.At subsequent timepoints (days 10 and 35) no differences in BMP-7 or noggin staining
could be seen among the groups. No significant staining for noggin or BMP-7 could be ascertained in Ad-GFP-treated specimens (n = 2 to 4
specimens/group; hematoxylin counterstain; 10× original magnification; coronal orientation to sections).
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improvements in all parameters of periodontal wound
healing for lesions treated by BMP-7 gene delivery
(Fig. 8). There was nearly a 4-fold increase in new
cementum length and a 9-fold increase in bone vol-
ume in defects treated with Ad-BMP-7 versus control
(Ad-GFP) treatment (P <0.01; Fig. 8). There was a
modest reduction in bone area and length of new bone
by noggin gene delivery as compared to GFP treat-
ment, while no difference seen for cementogenesis.
Interestingly, ectopic bone formation was noted in all
specimens treated with Ad-BMP-7 and was located
immediately lateral to the carrier in all directions. No
cartilage was seen in any of the defects at 35 days.
Minimal evidence of inflammation was seen at all sites
at this time period as well.
DISCUSSION
To date, predictable periodontal
regeneration has been elusive in
the field of periodontology. The
complex microenvironment of
the periodontal wound creates
many challenges in the repair of
periodontal osseous lesions.30
The field of tissue engineering
has provided alternative method-
ologies to repair tissue defects
combining transplantation biol-
ogy with scaffolding devices for
delivery of cells, genes, or pro-
teins.1 Our approach of ex vivo
gene transfer of BMPs to peri-
odontal wounds can be consid-
ered as an extension of the tis-
sue engineering concept. The
BMPs have demonstrated much
success in regenerating peri-
odontal31 and peri-implant32
bone defects (see reference 33
for review). In most of the peri-
odontal studies, both alveolar
bone and cementum were pre-
dictably regenerated.
Despite many of the positive
results of using BMPs for peri-
odontal regeneration, several lim-
itations persist. Depending on the
carrier or dose applied, varying
degrees of ankylosis has been
noted.34 Furthermore, drug insta-
bility at the site of delivery con-
tributes to the need of pharma-
cologic dosing, which is limited
by local and systemic toxicity.35
The therapeutic delivery of BMPs
requires a well-characterized
delivery system to safely target
the factors to the wound. Recent studies of pharmaco-
kinetic release profiles for rhBMP-2 typically consist of
an initial burst followed by a secondary release phase
characterized by a t1/2 of 1 to 10 days.36,37 A few
human trials using BMPs reported to date have uti-
lized superphysiological doses of BMPs that result in
“dose-dumping” of potent morphogens in the wound
site.15,38,39 This use of bolus delivery can lead to sys-
temic toxicity,40 likely through cytokine diffusion into
the bloodstream.41
This approach using ex vivo gene transfer of SDFs
provided a more robust response in the stimulation of
osteogenesis as compared to our previous efforts using
direct gene transfer42 (and unpublished data). Indeed,
our group and others have demonstrated more potent
Figure 4.
Descriptive histology of periodontal wound repair 10 days following adenoviral gene transfer of BMP-7
and noggin. 10 days following ex vivo gene transfer to periodontal wounds, block biopsies were taken
and descriptive histology was performed to assess the wound healing following gene delivery. Panels
a, c, and e show coronal slide orientations of Ad-GFP,Ad-noggin and Ad-BMP-7 treatments at low
power (4×) magnification, respectively, and panels b, d and f show high power (10×) magnification
of corresponding treatment groups. Note minimal healing overall in all of the groups treated (black
arrows depicting margins of the osseous lesions). However, in Ad-BMP-7 treated specimens cartilage
could be seen in 3 of 4 specimens (asterisk; panel e) with islands of bone lateral to the carrier matrix
(panel e, open arrows) In the Ad-BMP-7-treated specimens, cells were visualized closely associated
with the root surface (panel f, arrows).
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effects in stimulating osteogenesis using ex vivo tech-
niques.20,21,43 Several groups have shown positive
results for bone repair with direct nonviral gene trans-
fer in immunocompetent animals using parathyroid
hormone with or without BMP-4.44,45 The delivery of
naked DNA via polymer matrix sponges termed “gene-
activated matrices” or GAMs are effective for uptake of
genes in orthotopic wounds. This approach and others
such as microseeding46 offer potential for in vivo gene
transfer to periodontal wounds.
Additional studies will be needed to determine the
feasibility of BMP-gene therapy in other more relevant
larger animal model systems possessing a pathologi-
cally-exposed tooth surface and kinetic healing profile
more similar to the human situation.47 Although this
model does not represent a critical size defect for peri-
odontal regeneration, it serves as a reasonable screen-
ing model to examine wound healing kinetics. Indeed,
King and colleagues have successfully and extensively
used this model to measure the tissue healing
responses of BMPs.29,48,49
A major consideration in using adenovirus for gene
transfer is the significant cytotoxic T-cell-mediated
immune response that occurs when delivered in vivo.50
Despite the inflammatory cell infiltrate that was notable
3 days after gene transfer, the majority of inflamma-
tion in our model was decreased by 10 days and was
still successful in evoking a potent chondrogenic and
osteogenic response. Other investigators have
attempted to circumvent the problems of the immune
response inhibiting Ad-BMP-induced bone formation
by using immunodeficient animals for study in long
bone,20,43 ectopic51 and mandibular ramus52 defects.
By using the ex vivo gene transfer approach we were
better able to reproducibly regenerate these bony
defects while studying the effects of gene therapy in
immuncompetent animals. Krebsbach et al. have
shown that transduced SDFs elicit the formation of
newly formed bone that is a chimera of both donor
and recipient cells.21 BMP transduced fibroblasts from
gingiva, dermis, periodontal ligament, and dental pulp
all produce bone upon implantation in orthotopic and
ectopic sites53 (and unpublished data). BMP trans-
duced fibroblasts also form the “mineralizing tissue”
in diffusion chambers implanted in vivo that appears
identical to that produced by calvarial periosteal digest
cells.54 These are the definitive data that BMP trans-
duction converts dermal fibroblasts to osteoblasts.
These data suggest that non-osteogenic cells can be
genetically modified to not only serve as a reservoir
for paracrine effects of BMP delivery, but also promoting
the differentiation of fibroblasts into osteoblasts.54 By
the use of real time PCR with a detection limit of about
2 picograms viral DNA/106 cells, the implanted cells
Figure 5.
Ad-BMP-7-mediated periodontal bone regeneration forms via a cartilage intermediate. Specimens evaluated at 10 and 21 days following gene transfer
with Ad-BMP-7 demonstrated evidence of islands of cartilage and chondroblast-like cells (day 10 specimens) or associated with bone-like tissue (day 21
specimens, middle and last columns). Note presence of immature woven bone (open arrows, day 10 top panel) and an island of cartilage, (top and
bottom panels). At day 21, more mature cartilage associated intimately with newly formed bone that was consistent with chondroblasts and a
cartilaginous matrix (last column) (H & E and toluidine blue staining 10× original magnification, days 10 and 21; 20× original magnification, high power).
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Figure 7.
BMP-7 gene transfer stimulates
cementogenesis and fibrous attachment in
vivo. Ex vivo gene transfer of SDFs
transduced by Ad-BMP-7 were
transplanted to periodontal alveolar
defects.A thin layer of new cementum
(black arrowheads) can be seen over the
denuded root surface 35 days following
surgery (a). Panel b reveals polarized
light microscopy revealing the presence of
fibers consistent with nascent Sharpey’s
fibers emanating from the immature
cemental surface (red arrowheads). (H&E
staining and polarized light; 40× original
magnification).
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and virus remain at the site of the
implant, albeit at low levels. After
about 3 weeks, the presence of
virus genome is not detectable at
the graft site. Our immunohisto-
chemical data suggest the BMP-
7 protein is detectable for <7
days. Although the gene expres-
sion profile is relatively short, the
high level production of BMP-7 in
the transplanted fibroblasts (0.2-
0.5 µg/106 cells) is sufficient to
elicit a potent osteogenic effect.
Although doses released by the
cells within the periodontal defect
are difficult to measure, it is spec-
ulated the levels of BMP released
in this model are significantly less
than those delivered by conven-
tional protein delivery approaches.
Future studies utilizing other gene
therapy vectors may extend the
expression profile of osteotropic
factors in vivo.
Our data also shows that nog-
gin, the competitive inhibitor of
BMP-activity tended to decrease
several parameters of periodontal
bone regeneration although did
not reach the P <0.05 significance
level (Fig. 8). Noggin is an
inhibitor of several BMP molecules
including BMP-2, −4 and, to a
lesser extent, BMP-7. Noggin
knockout mice die at the time of
birth and demonstrate coarse and
thickened bones suggestive of the
inhibitory role of noggin on
periosteal bone growth. Recently
noggin has been also shown to
inhibit membranous ossification
Figure 6.
Ex vivo gene transfer of BMP-7 stimulates periodontal tissue regeneration. Block biopsies harvested
35 days following gene transfer of Ad-GFP,Ad-noggin, or Ad-BMP-7. Panels a, c, and e demonstrate
low power magnification (×4) of typical specimens harvested following treatment.The black arrows
demarcate the borders of the original osseous lesions. Note minimal bridging of the osseous defect in
the Ad-GFP-treated specimen, with essentially no bridging of the bone defect in the Ad-noggin
specimen. Defects treated with Ad-BMP-7 demonstrated evidence of extensive periodontal bone
regeneration with complete bridging.The open arrows show islands of ectopic bone that were seen in
all of the Ad-BMP-7 specimens lateral to the carrier material. Panels b, d, and f reveal at high
magnification (×20). Note minimal evidence of cementogenesis and insertion of fibers to the
denuded tooth root surfaces in Ad-GFP and Ad-noggin treated specimens while the Ad-BMP-7-
treated site shows evidence of a thin layer of cementum-like material and evidence of a fibrous
attachment to the tooth root surface (H & E staining; n = 4 to 7 animals/group).
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in titanium bone chambers.55 Although noggin did not
appear to have a major inhibitory effect on blocking
osteogenesis as compared to control in our study, this
finding was likely due in part to the nature of the model
used (i.e., limited healing with the control at 35 days).
Therefore, investigations examining the effects of nog-
gin on periodontal bone and cementum formation dur-
ing periodontal repair in smaller defects are warranted.
Our finding that BMP-7 transduced fibroblasts stimu-
late noggin production in this model suggests that the
antagonism of BMP-action via noggin may in part
explain the persistence and maintenance of the peri-
odontal ligament space during osteogenesis. Indeed,
diffuse ankylosis despite administering high levels of
BMPs to defects is rare with the exception of sub-
merged bone defects.31,34 It has been previously shown
that BMP-7 and noggin have a coordinated expression
pattern during skeletogenesis56 and that other BMPs
stimulate noggin production.57 We have also found
that noggin gene expression is upregulated in cultured
PDL fibroblasts (unpublished data). Thus, the PDL/tooth
signal to prevent ankylosis and retain the PDL com-
partment may emanate from noggin. Future studies
examining noggin gene and protein expression fol-
lowing BMP delivery need to be carefully explored.
We conclude from this study that: 1) ex vivo gene
transfer of Ad-BMP-7 to SDFs releases BMP-7 protein
that stimulates periodontal wound healing including
bone, PDL, and cementum; 2) ex vivo gene transfer
of Ad-noggin tends to decrease periodontal bone repair;
and 3) the use of BMP-7 gene transfer offers an alter-
native approach for the delivery of growth factors for
periodontal tissue engineering.
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